Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.
hyperlipidemia
hypertension
metabolic syndrome
primary biliary cholangitis
type 2 diabetes mellitus
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2023
accepted:
19
04
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Metabolic risk factors in primary biliary cholangitis (PBC) have not been well described in China. Additionally, it is unclear whether these factors have an impact on the prognosis of PBC patients. Therefore, this study aimed to investigate the prevalence of main metabolic risk factors in PBC, and to evaluate their prognostic values for liver-related outcomes. A cohort of 789 PBC patients was retrospectively studied between July 2008 and September 2019 by investigating the main metabolic risk factors and analyzing liver-related outcomes. At presentation, 271 (34.3%) patients had concomitant hyperlipidemia, 126 (16.0%) had hypertension, 94 (11.9%) had type 2 diabetes mellitus (T2DM), and 17 (2.2%) had nonalcoholic fatty liver disease (NAFLD). Hyperlipidemia was found to be associated with the lower risk of liver-related death [ Hyperlipidemia, hypertension, and T2DM were found as main metabolic risk factors in PBC in China. Hyperlipidemia indicated a benign clinical outcome of PBC, while hypertension indicated a poor outcome of PBC. Older age and cirrhosis had superimposition effects on hypertension for liver-related poor outcomes. Anti-sp100 might be associated with adverse outcomes, especially in PBC patients with hypertension.
Sections du résumé
Background
UNASSIGNED
Metabolic risk factors in primary biliary cholangitis (PBC) have not been well described in China. Additionally, it is unclear whether these factors have an impact on the prognosis of PBC patients. Therefore, this study aimed to investigate the prevalence of main metabolic risk factors in PBC, and to evaluate their prognostic values for liver-related outcomes.
Methods
UNASSIGNED
A cohort of 789 PBC patients was retrospectively studied between July 2008 and September 2019 by investigating the main metabolic risk factors and analyzing liver-related outcomes.
Results
UNASSIGNED
At presentation, 271 (34.3%) patients had concomitant hyperlipidemia, 126 (16.0%) had hypertension, 94 (11.9%) had type 2 diabetes mellitus (T2DM), and 17 (2.2%) had nonalcoholic fatty liver disease (NAFLD). Hyperlipidemia was found to be associated with the lower risk of liver-related death [
Conclusion
UNASSIGNED
Hyperlipidemia, hypertension, and T2DM were found as main metabolic risk factors in PBC in China. Hyperlipidemia indicated a benign clinical outcome of PBC, while hypertension indicated a poor outcome of PBC. Older age and cirrhosis had superimposition effects on hypertension for liver-related poor outcomes. Anti-sp100 might be associated with adverse outcomes, especially in PBC patients with hypertension.
Identifiants
pubmed: 38027142
doi: 10.3389/fendo.2023.1142177
pmc: PMC10663935
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1142177Informations de copyright
Copyright © 2023 Zhao, Yan, Han, Zhang, Zhao and Liao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hepatol Int. 2019 Nov;13(6):788-799
pubmed: 31552558
Clin Drug Investig. 2014 Jan;34(1):1-7
pubmed: 24081374
Liver Int. 2016 Jul;36(7):936-48
pubmed: 26972930
Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G970-9
pubmed: 12606306
Am J Gastroenterol. 2019 Jan;114(1):48-63
pubmed: 30429590
Gut. 2006 Dec;55(12):1795-800
pubmed: 16632556
Hepatology. 1991 Apr;13(4):663-9
pubmed: 2010161
Hepatology. 2019 Jan;69(1):394-419
pubmed: 30070375
Eur J Gastroenterol Hepatol. 2021 Apr 1;33(4):565-570
pubmed: 32541239
Hepatology. 1999 Dec;30(6):1356-62
pubmed: 10573511
BMJ. 2020 Apr 28;369:m997
pubmed: 32345662
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
Hepatology. 1992 May;15(5):858-62
pubmed: 1568727
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Gut. 2005 Apr;54(4):528-32
pubmed: 15753539
Lancet. 2011 May 7;377(9777):1600-9
pubmed: 21529926
Dig Dis Sci. 2011 Sep;56(9):2750-7
pubmed: 21409375
J Gastroenterol Hepatol. 2019 Jul;34(7):1236-1241
pubmed: 30365184
Gut. 2002 Aug;51(2):265-9
pubmed: 12117892
N Engl J Med. 2005 Sep 22;353(12):1261-73
pubmed: 16177252
Atherosclerosis. 2014 Jan;232(1):99-109
pubmed: 24401223
Hepatology. 2007 Jan;45(1):118-27
pubmed: 17187436
Hepatol Res. 2015 Nov;45(11):1055-61
pubmed: 25689394
Pharmacol Res. 2019 Aug;146:104333
pubmed: 31254667
Int J Clin Exp Med. 2014 Sep 15;7(9):2921-4
pubmed: 25356160
Liver Int. 2021 Mar;41(3):535-544
pubmed: 33022821
Gastroenterology. 2003 Mar;124(3):854-6
pubmed: 12612923
Hepatology. 1997 Nov;26(5):1123-30
pubmed: 9362351
Liver Int. 2016 Jan;36 Suppl 1:100-4
pubmed: 26725905
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):195-203
pubmed: 29804393
J Dig Dis. 2019 Apr;20(4):163-173
pubmed: 30444584
Clin Gastroenterol Hepatol. 2017 Dec;15(12):1940-1949.e8
pubmed: 28419855
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
World J Gastroenterol. 2020 Dec 7;26(45):7088-7103
pubmed: 33362370
Clin Chim Acta. 2012 Aug 16;413(15-16):1211-6
pubmed: 22503841
Mol Cell Endocrinol. 2022 May 15;548:111618
pubmed: 35283218
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Front Immunol. 2023 Jan 04;13:1098076
pubmed: 36685575
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jan 24;48(1):10-46
pubmed: 32008294
Hepatology. 2023 May 1;77(5):1797-1835
pubmed: 36727674
Curr Hypertens Rep. 2019 Jun 24;21(8):63
pubmed: 31236708
Hepatology. 1995 Jan;21(1):89-95
pubmed: 7806174
Gastroenterology. 1989 Dec;97(6):1506-13
pubmed: 2583416
Am J Physiol Gastrointest Liver Physiol. 2001 Apr;280(4):G584-94
pubmed: 11254484